Skip to content

Study · Randomized controlled trial · n = 2,539 · 2025

11 results

Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study.

Evans M, Evans W, Godbeer F, Edgar L, Spaepen E, Davies AL

Advances in therapy18 Apr 2025Cited by 4 (Europe PMC)

PMID40251452 (opens in a new tab)PMCIDPMC12085389 (opens in a new tab)DOI10.1007/s12325-025-03194-8 (opens in a new tab)PepBankPUB-40251452
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study11

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1 participants, tirzepatide produced significant weight loss, with greater reductions at higher doses.

    In plain wordsIn a large obesity trial, tirzepatide led to clear weight loss, and higher doses led to more weight loss.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight loss over 72 weeks by dose
    Study

    n = 2,539

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    5, 10 and 15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide demonstrated significant weight loss, with greater reductions at higher doses.
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

Studies that did not test the peptide alone10

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 02HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the drug cost per kilogram of weight lost at 72 weeks with tirzepatide 5 mg was £102.86.

    In plain wordsIn a UK cost analysis, each kilogram lost on tirzepatide 5 mg cost £102.86 in drug costs over 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCost per kilogram of weight loss at 72 weeks, 5 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Cost per kilogram of weight loss
    102.86 £
    tirzepatide 5 mg

    Source sentences

    Summary
    Cost/kilogram of weight loss at 72W was £102.86, £85.41, and £89.24 for 5, 10, and 15 mg, respectively.
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 03HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the drug cost per kilogram of weight lost at 72 weeks with tirzepatide 10 mg was £85.41.

    In plain wordsIn a UK cost analysis, each kilogram lost on tirzepatide 10 mg cost £85.41 in drug costs over 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCost per kilogram of weight loss at 72 weeks, 10 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Cost per kilogram of weight loss
    85.41 £
    tirzepatide 10 mg

    Source sentences

    Summary
    Cost/kilogram of weight loss at 72W was £102.86, £85.41, and £89.24 for 5, 10, and 15 mg, respectively.
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 04HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the drug cost per kilogram of weight lost at 72 weeks with tirzepatide 15 mg was £89.24.

    In plain wordsIn a UK cost analysis, each kilogram lost on tirzepatide 15 mg cost £89.24 in drug costs over 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCost per kilogram of weight loss at 72 weeks, 15 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Cost per kilogram of weight loss
    89.24 £
    tirzepatide 15 mg

    Source sentences

    Summary
    Cost/kilogram of weight loss at 72W was £102.86, £85.41, and £89.24 for 5, 10, and 15 mg, respectively.
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  4. 05HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the average per-patient cost for 5% weight loss at 72 weeks with tirzepatide 5 mg was £1852.

    In plain wordsIn a UK cost analysis, reaching 5% weight loss on tirzepatide 5 mg cost an average of £1852 per person.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePer-patient cost for 5% weight loss, 5 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Average per-patient cost for 5% weight loss
    1852 £
    tirzepatide 5 mg

    Source sentences

    Summary
    Average per-patient costs at 72W for 5% weight loss were £1852, £1971, and £2186 (5, 10, and 15 mg, respectively; average 28-day costs: £102.90, £109.52, and £121.47).
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 06HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the average per-patient cost for 5% weight loss at 72 weeks with tirzepatide 10 mg was £1971.

    In plain wordsIn a UK cost analysis, reaching 5% weight loss on tirzepatide 10 mg cost an average of £1971 per person.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePer-patient cost for 5% weight loss, 10 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Average per-patient cost for 5% weight loss
    1971 £
    tirzepatide 10 mg

    Source sentences

    Summary
    Average per-patient costs at 72W for 5% weight loss were £1852, £1971, and £2186 (5, 10, and 15 mg, respectively; average 28-day costs: £102.90, £109.52, and £121.47).
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  6. 07HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the average per-patient cost for 5% weight loss at 72 weeks with tirzepatide 15 mg was £2186.

    In plain wordsIn a UK cost analysis, reaching 5% weight loss on tirzepatide 15 mg cost an average of £2186 per person.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePer-patient cost for 5% weight loss, 15 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Average per-patient cost for 5% weight loss
    2186 £
    tirzepatide 15 mg

    Source sentences

    Summary
    Average per-patient costs at 72W for 5% weight loss were £1852, £1971, and £2186 (5, 10, and 15 mg, respectively; average 28-day costs: £102.90, £109.52, and £121.47).
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  7. 08HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the average per-patient cost for 10% weight loss with tirzepatide 5 mg was £2258.

    In plain wordsIn a UK cost analysis, reaching 10% weight loss on tirzepatide 5 mg cost an average of £2258 per person.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePer-patient cost for 10% weight loss, 5 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Average per-patient cost for 10% weight loss
    2258 £
    tirzepatide 5 mg

    Source sentences

    Summary
    Average per-patient costs for 10% weight loss were £2258, £2209, and £2338 (28-day costs: £125.43, £122.69, and £129.88).
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  8. 09HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the average per-patient cost for 10% weight loss with tirzepatide 10 mg was £2209.

    In plain wordsIn a UK cost analysis, reaching 10% weight loss on tirzepatide 10 mg cost an average of £2209 per person.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePer-patient cost for 10% weight loss, 10 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Average per-patient cost for 10% weight loss
    2209 £
    tirzepatide 10 mg

    Source sentences

    Summary
    Average per-patient costs for 10% weight loss were £2258, £2209, and £2338 (28-day costs: £125.43, £122.69, and £129.88).
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  9. 10HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, the average per-patient cost for 10% weight loss with tirzepatide 15 mg was £2338.

    In plain wordsIn a UK cost analysis, reaching 10% weight loss on tirzepatide 15 mg cost an average of £2338 per person.

    Peptide
    Tirzepatide
    Outcome
    Not applicablePer-patient cost for 10% weight loss, 15 mg
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Measurements

    Average per-patient cost for 10% weight loss
    2338 £
    tirzepatide 15 mg

    Source sentences

    Summary
    Average per-patient costs for 10% weight loss were £2258, £2209, and £2338 (28-day costs: £125.43, £122.69, and £129.88).
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  10. 11HumanNot a test of Tirzepatide aloneOther designOther

    In a UK analysis of SURMOUNT-1, tirzepatide 15 mg was the most cost-efficient dose for achieving the higher weight loss targets of 15% and 20%.

    In plain wordsIn a UK cost analysis, tirzepatide 15 mg cost least per person to reach 15% and 20% weight loss.

    Peptide
    Tirzepatide
    Outcome
    Not applicableCost-efficiency for 15% and 20% weight loss targets
    Study

    n: not reported in source

    Outcome group
    Healthcare costs and utilization · Whole body

    Source sentences

    Summary
    The 15 mg dose was the most cost-efficient for achieving higher weight loss targets (15% and 20%).
    1 context sentence
    Summary · context
    Data from SURMOUNT-1 (2539 participants across global sites) were used to assess tirzepatide's (5, 10, and 15 mg) impact on weight reduction over 72 weeks (72W), with a focus on drug acquisition costs and cost/weight loss outcome.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.